Clinical Trials Browser

Completed × Carcinoma, Non-Small-Cell Lung × Crizotinib × Clear all

Carcinoma, Non-Small-Cell Lung

NCT05834348 2025-03-30

DELINOR

Completed

5,279 enrolled 10 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01970865 2024-08-12

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

Phase 1/2 Completed

364 enrolled 89 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02679170 2024-08-09

Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)

Completed

692 enrolled 25 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01712217 2024-08-02

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

Phase 1/2 Completed

220 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03088930 2022-02-11

Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer

Phase 2 Completed

3 enrolled 7 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02737501 2021-08-20

ALTA-1L

Phase 3 Completed

275 enrolled 23 charts 2 FDA

Thoracic

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell

NCT02574078 2021-05-06

CheckMate370

Phase 1/2 Completed

341 enrolled 28 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01945021 2021-02-21

Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC

Phase 2 Completed

129 enrolled 16 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT01639001 2020-12-08

A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

Phase 3 Completed

207 enrolled 29 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01597258 2019-09-13

Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan)

Completed

2,029 enrolled 8 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01998126 2018-04-02

Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer

Phase 1 Completed

14 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00932451 2017-01-13

An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Phase 2 Completed

1,069 enrolled 19 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00965731 2015-10-28

Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer

Phase 1 Completed

27 enrolled 22 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01121575 2015-10-28

A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer

Phase 1 Completed

70 enrolled 50 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

ALEX

DELINOR

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer

ALTA-1L

CheckMate370

Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC

A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan)

Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer

An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer

A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer